Neuen BL, Heerspink HJL, Vart P, Claggett BL, et al. Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067584.
PMID: 37952217